Results 241 to 250 of about 188,451 (293)
Some of the next articles are maybe not open access.
Hematology, 2001
AbstractThe treatment recommendations for chronic myelogenous leukemia (CML) are evolving rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor, have become commercially available and non-myeloablative stem cell transplants continue to be refined.
B J, Druker +5 more
+11 more sources
AbstractThe treatment recommendations for chronic myelogenous leukemia (CML) are evolving rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor, have become commercially available and non-myeloablative stem cell transplants continue to be refined.
B J, Druker +5 more
+11 more sources
Journal of the American Medical Association, 1924
Irradiation treatment of chronic myelogenous leukemia was first undertaken by Senn 1 in 1903, using long wave length roentgen rays. It was not until after Renon, Degrais and Desbouis, 2 in 1913, and Ordway, 3 in 1917, reported the effect of radium on the disease that adequate irradiation was given at all frequently so as to produce very often marked ...
GEORGE R. MINOT +2 more
openaire +2 more sources
Irradiation treatment of chronic myelogenous leukemia was first undertaken by Senn 1 in 1903, using long wave length roentgen rays. It was not until after Renon, Degrais and Desbouis, 2 in 1913, and Ordway, 3 in 1917, reported the effect of radium on the disease that adequate irradiation was given at all frequently so as to produce very often marked ...
GEORGE R. MINOT +2 more
openaire +2 more sources
Current Opinion in Hematology, 1999
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Current Opinion in Hematology, 1995
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Current Opinion in Oncology, 1994
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
Current Opinion in Oncology, 2003
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +4 more sources
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +4 more sources
Juvenile Chronic Myelogenous Leukemia
Journal of Pediatric Hematology/Oncology, 1988Juvenile chronic myelogenous leukemia (JCML) is a malignant hematopoietic disorder of monocyte-histiocyte lineage that affects children less than 4 years of age. Since the disease represents only 2% of all childhood leukemias, experience with it has been limited even in large centers.
M H, Freedman, Z, Estrov, H S, Chan
openaire +2 more sources
Clinical Journal of Oncology Nursing, 2005
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources